Guangdong Academy of Geriatrics

Guangzhou, China

Guangdong Academy of Geriatrics

Guangzhou, China
SEARCH FILTERS
Time filter
Source Type

Wang C.,Guangzhou University of Chinese Medicine | Min C.,Guangdong Academy of Geriatrics | Rong X.,Guangzhou University of Chinese Medicine | Fu T.,Guangdong Academy of Geriatrics | And 2 more authors.
Discovery Medicine | Year: 2015

Aim. Diabetic nephropathy (DN) is the most frequent cause of end-stage renal disease. The activation of the renin-angiotensin system (RAS) and lipid disorders are major risk factors in progressive chronic kidney disease. Inhibition of the RAS is one of the most widely used therapies to treat chronic kidney disease. But its effect is not sufficient, and lowered hyperlipidemia is required. Most of medications for hypertension have effects only on the blood pressure in DN. This study is to evaluate the influence of irbesartan on blood lipid, kidney function, and the pathological change of kidney, liver, and adipose tissue. Methods. Six-week old db/db mice were randomly assigned to control group and irbesartan group. Mice in irbesartan group were fed 40 mg/kg irbesartan each day. Eight weeks later, blood lipid, kidney function, and the pathological change of kidney, liver, and adipose tissue were measured. Results. The results indicated that the blood lipid, uric acid, urea nitrogen, and creatinine of db/db mice increased significantly. There are obvious vacuolar degeneration and ballooned hepatocytes around the central vein of db/db mouse liver. Kidney biopsy found glomerular hypertrophy of glomerular, mesangial thickening, and vacuolar degeneration. Irbesartan can decrease the blood pressure, blood lipid, and kidney lipid. But it has no effects on blood glucose and liver lipid. It can improve the function and pathological change of kidney of db/db mice. But it has no effects on pathological change of adipose tissue and liver. Conclusions. Irbesartan can decrease blood lipid and protect the kidney of db/db mice, and is a good choice of treatment for diabetic nephropathy. © 2015, Discovery Medicine.


PubMed | Guangzhou University of Chinese Medicine and Guangdong Academy of Geriatrics
Type: Journal Article | Journal: Discovery medicine | Year: 2015

Diabetic nephropathy (DN) is the most frequent cause of end-stage renal disease. The activation of the renin-angiotensin system (RAS) and lipid disorders are major risk factors in progressive chronic kidney disease. Inhibition of the RAS is one of the most widely used therapies to treat chronic kidney disease. But its effect is not sufficient, and lowered hyperlipidemia is required. Most of medications for hypertension have effects only on the blood pressure in DN. This study is to evaluate the influence of irbesartan on blood lipid, kidney function, and the pathological change of kidney, liver, and adipose tissue.Six-week old db/db mice were randomly assigned to control group and irbesartan group. Mice in irbesartan group were fed 40 mg/kg irbesartan each day. Eight weeks later, blood lipid, kidney function, and the pathological change of kidney, liver, and adipose tissue were measured.The results indicated that the blood lipid, uric acid, urea nitrogen, and creatinine of db/db mice increased significantly. There are obvious vacuolar degeneration and ballooned hepatocytes around the central vein of db/db mouse liver. Kidney biopsy found glomerular hypertrophy of glomerular, mesangial thickening, and vacuolar degeneration. Irbesartan can decrease the blood pressure, blood lipid, and kidney lipid. But it has no effects on blood glucose and liver lipid. It can improve the function and pathological change of kidney of db/db mice. But it has no effects on pathological change of adipose tissue and liver.Irbesartan can decrease blood lipid and protect the kidney of db/db mice, and is a good choice of treatment for diabetic nephropathy.


Min C.,Guangdong Academy of Geriatrics | Peng C.,Guangdong Academy of Geriatrics | Wei G.,Guangdong Academy of Geriatrics | Huang X.,Guangdong Academy of Geriatrics | And 3 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015

Allergic rhinitis (AR) is a chronic inflammatory disease of rhino-ocular mucosa, affecting up to 40% of population worldwide. Chinese herbal medicines and Acupuncture, adopted thousands of years in China, has good effect on allergic rhinitis. This study evaluates the effects of Moxibustion with Chinese herbal in treating patients with allergic rhinitis over a 1-year follow-up. A randomized controlled trial was conducted in a sample of 355 participants recruited from Guangdong general hospital of China. After baseline measurements, participants were randomly assigned to treatment-group or control group. Treatment group received Moxibustion with Chinese herbal. Control group received Loratadine. The main outcomes, including symptom severity and quality of life were measured using the Allergic Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Both moxibustion with Chinese herbal and Loratadine improve nose symptoms such as stuffy/blocked, sneezing, runny nose, itchy nose, sore nose and post-nasal drip in patients with AR. Symptoms fatigue, loss of taste, afraid of cold/wind and cold limb were improved significantly in moxibustion with Chinese herbal group. The mean quality of life scores decreased in both groups after treatment. Compare to control group, moxibustion with Chinese herbal is more effective than Loratadine in improving the quality of life in patients with AR. The results show moxibustion with Chinese herbal was effective to reduce symptoms and enhance quality of life in patients with allergic rhinitis. It is a simple, convenient and economic therapy for patients with AR. Further controlled trials of its effects in patients with allergic rhinitis are recommended. © 2015, E-Century Publishing Corporation. All rights reserved.

Loading Guangdong Academy of Geriatrics collaborators
Loading Guangdong Academy of Geriatrics collaborators